No local treatment except white vaseline was used ... Eleven patients with severe and persistent psoriasis vulgaris were maintained on a restricted diet allowing 150 to 300 international units ...

Dovobet ® is a compounded combination of calcipotriol [also calcipotriene] and betamethasone diproprionate, and is used for psoriasis vulgaris ... option in the treatment of psoriasis.

Several anti-TNF drugs have been used successfully to treat psoriasis and PsA. Infliximab, a chimeric anti-TNF monoclonal antibody administered by intravenous infusion, was the first TNF blocker ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab. Jefferies upgraded its rating to 'Hold' with a target of ₹400, citing ...

Even before the recent development of biological agents, a long list of effective treatments has been available for patients with psoriasis. Topical therapies such as corticosteroids, vitamin D ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

A wearable blue-light device differs greatly from the phototherapy treatments that you receive at a hospital or psoriasis treatment center. The US Food and Drug Administration (FDA) has approved a ...

According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 82% phase transition success ... ESK-001 is under development for the treatment of systemic lupus ...

Acne vulgaris is a common skin condition that affects ... which can lead to scarring and emotional distress. Treatment options for acne have evolved over the years, with a growing interest in ...

According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success ... inflammatory bowel disease (IBD); KBLP-002 program for the treatment of asthma ...

Before developing erythrodermic psoriasis, they often notice that their psoriasis is worsening or not improving with treatment. If you notice either of these happening, see a board-certified ...